US Stock MarketDetailed Quotes
LYRA Lyra Therapeutics
- 0.275
- -0.005-1.93%
Trading Jul 22 10:36 ET
16.74MMarket Cap-234P/E (TTM)
0.280High0.271Low278.52KVolume0.280Open0.280Pre Close76.69KTurnover0.74%Turnover RatioLossP/E (Static)60.96MShares6.79052wk High0.22P/B10.34MFloat Cap0.25352wk Low--Dividend TTM37.65MShs Float22.000Historical High--Div YieldTTM3.18%Amplitude0.253Historical Low0.275Avg Price1Lot Size
Lyra Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -41.67%-22.46M | -45.91%-63.3M | -56.68%-19.06M | -30.13%-14.11M | -68.62%-14.28M | -33.14%-15.85M | -68.03%-43.39M | -7.67%-12.16M | -5.16%-10.85M | -350.52%-8.47M |
| Net income from continuing operations | -38.12%-22.45M | -13.39%-62.68M | -6.47%-15.16M | -5.99%-15.65M | -8.72%-15.62M | -36.47%-16.26M | -27.04%-55.28M | -4.54%-14.24M | -33.57%-14.77M | -30.14%-14.37M |
| Depreciation and amortization | -52.11%136K | -73.95%278K | -61.71%85K | -124.37%-68K | -108.04%-23K | 1.43%284K | 6.59%1.07M | -20.14%222K | -20.29%279K | -5.61%286K |
| Change In working capital | -79.29%-1.37M | -207.24%-4.89M | -498.50%-4.38M | -35.86%1.22M | -121.34%-961K | 31.75%-763K | -67.28%4.56M | -158.10%-732K | 656.14%1.9M | -66.55%4.5M |
| -Change in prepaid assets | -130.49%-257K | 213.48%867K | 151.01%302K | 40.63%-570K | -29.98%292K | 127.22%843K | 9.80%-764K | -201.37%-592K | 44.44%-960K | 90.41%417K |
| -Change in payables and accrued expense | -72.67%267K | -17.79%1.94M | -396.15%-1.42M | 0.65%3.1M | -325.16%-716K | 230.27%977K | -34.31%2.36M | -119.58%-286K | 118.06%3.08M | -74.60%318K |
| -Change in other current assets | 87.50%-256K | -241.68%-4.93M | -97.36%-2.77M | -205.31%-436K | 173.64%324K | -14,528.57%-2.05M | -423.32%-1.44M | -441.31%-1.4M | 73.95%414K | -287.23%-440K |
| -Change in other current liabilities | -372.00%-590K | -258.32%-1.21M | -122.51%-351K | -20.96%-329K | -50.94%-403K | 51.36%-125K | 177.38%763K | 711.37%1.56M | -8.80%-272K | -8.98%-267K |
| -Change in other working capital | -29.76%-532K | -142.84%-1.56M | -1,227.27%-146K | -51.53%-544K | 12.76%-458K | -109.05%-410K | -68.95%3.64M | 95.94%-11K | -2,464.29%-359K | ---525K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -41.67%-22.46M | -45.91%-63.3M | -56.68%-19.06M | -30.13%-14.11M | -68.62%-14.28M | -33.14%-15.85M | -68.03%-43.39M | -7.67%-12.16M | -5.16%-10.85M | -350.52%-8.47M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 47.83%7.86M | 80.64%-12.58M | 96.36%-2.36M | -51,551.72%-14.98M | -3,907.14%-561K | 5,815.05%5.32M | -1,820.41%-65.01M | -5,889.84%-64.87M | 94.39%-29K | 97.76%-14K |
| Net PPE purchase and sale | -4,675.56%-2.15M | -538.41%-1.05M | -2,710.71%-787K | -396.55%-144K | -407.14%-71K | 51.61%-45K | 95.16%-164K | 97.41%-28K | 94.39%-29K | 97.76%-14K |
| Net investment purchase and sale | 86.68%10.01M | 82.21%-11.54M | 97.58%-1.57M | ---14.84M | ---490K | --5.36M | ---64.84M | ---64.84M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 47.83%7.86M | 80.64%-12.58M | 96.36%-2.36M | -51,551.72%-14.98M | -3,907.14%-561K | 5,815.05%5.32M | -1,820.41%-65.01M | -5,889.84%-64.87M | 94.39%-29K | 97.76%-14K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 216,000.00%8.64M | -31.75%65.69M | 18.92M | -77.12%-418K | -51.10%47.19M | -33.33%4K | 26,712.53%96.26M | 0 | -180.95%-236K | 52,055.14%96.49M |
| Net common stock issuance | ---- | -31.10%69.24M | --19.24M | --0 | ---- | ---- | --100.5M | --0 | --0 | ---- |
| Net preferred stock issuance | --8.81M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | -25.00%3K | 1,187.50%103K | --0 | --2K | --97K | -50.00%4K | -98.68%8K | --0 | --0 | --0 |
| Net other financing activities | ---169K | 13.94%-3.65M | ---322K | -77.97%-420K | ---- | ---- | -1,633.06%-4.25M | --0 | -148.42%-236K | ---4.01M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 216,000.00%8.64M | -31.75%65.69M | --18.92M | -77.12%-418K | -51.10%47.19M | -33.33%4K | 26,712.53%96.26M | --0 | -180.95%-236K | 52,055.14%96.49M |
| Net cash flow | ||||||||||
| Beginning cash position | -30.04%23.75M | -26.33%33.94M | -76.35%26.24M | -54.33%55.75M | -31.31%23.41M | -26.33%33.94M | -38.50%46.08M | 89.83%110.98M | 75.98%122.09M | -48.69%34.08M |
| Current changes in cash | 43.46%-5.95M | 15.96%-10.2M | 96.76%-2.5M | -165.60%-29.51M | -63.25%32.34M | 12.18%-10.53M | 57.94%-12.13M | -522.04%-77.03M | -1.80%-11.11M | 2,892.28%88M |
| End cash Position | -24.01%17.79M | -30.04%23.75M | -30.04%23.75M | -76.35%26.24M | -54.33%55.75M | -31.31%23.41M | -26.33%33.94M | -26.33%33.94M | 89.83%110.98M | 75.98%122.09M |
| Free cash flow | -54.79%-24.6M | -47.77%-64.35M | -62.77%-19.85M | -31.11%-14.26M | -69.18%-14.35M | -32.48%-15.9M | -49.11%-43.55M | 1.52%-12.19M | -0.41%-10.88M | -407.84%-8.48M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg